USD 16.02
(-15.68%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 11.61 Thousand USD | 0.0% |
2022 | - USD | 0.0% |
2021 | - USD | -100.0% |
2020 | 20 Thousand USD | 0.0% |
2019 | - USD | 0.0% |
2018 | - USD | 0.0% |
2017 | - USD | 0.0% |
2016 | - USD | 0.0% |
2015 | - USD | 0.0% |
2014 | - USD | 0.0% |
2013 | - USD | 0.0% |
2012 | - USD | 100.0% |
2011 | -34.36 Thousand USD | -211.14% |
2010 | 30.91 Thousand USD | 100.16% |
2009 | 15.44 Thousand USD | -67.04% |
2008 | 46.86 Thousand USD | 812.05% |
2007 | -6582.00 USD | -114.82% |
2006 | 44.41 Thousand USD | 146.42% |
2005 | -95.69 Thousand USD | -264.89% |
2004 | -26.22 Thousand USD | -14231.15% |
2003 | -183.00 USD | 0.0% |
2002 | - USD | 0.0% |
2001 | - USD | 0.0% |
2000 | - USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | - USD | -100.0% |
2024 Q1 | 12.5 Thousand USD | 202.64% |
2023 Q1 | - USD | 0.0% |
2023 FY | 11.61 Thousand USD | 0.0% |
2023 Q4 | 4131.00 USD | 0.02% |
2023 Q3 | 4130.00 USD | 23.32% |
2023 Q2 | 3349.00 USD | 0.0% |
2022 Q4 | - USD | 0.0% |
2022 FY | - USD | 0.0% |
2022 Q2 | - USD | 0.0% |
2022 Q3 | - USD | 0.0% |
2022 Q1 | - USD | 0.0% |
2021 Q3 | - USD | 0.0% |
2021 Q1 | - USD | -100.0% |
2021 Q4 | - USD | 0.0% |
2021 Q2 | - USD | 0.0% |
2021 FY | - USD | -100.0% |
2020 Q3 | - USD | 0.0% |
2020 Q2 | - USD | -100.0% |
2020 FY | 20 Thousand USD | 0.0% |
2020 Q1 | 20 Thousand USD | 0.0% |
2020 Q4 | 19.98 Million USD | 0.0% |
2019 Q4 | - USD | 0.0% |
2019 Q1 | - USD | 0.0% |
2019 Q2 | - USD | 0.0% |
2019 FY | - USD | 0.0% |
2019 Q3 | - USD | 0.0% |
2018 Q1 | - USD | 0.0% |
2018 Q3 | - USD | 0.0% |
2018 FY | - USD | 0.0% |
2018 Q4 | - USD | 0.0% |
2018 Q2 | - USD | 0.0% |
2017 FY | - USD | 0.0% |
2017 Q2 | - USD | 0.0% |
2017 Q1 | - USD | 0.0% |
2017 Q4 | - USD | 0.0% |
2017 Q3 | - USD | 0.0% |
2016 FY | - USD | 0.0% |
2016 Q4 | - USD | 0.0% |
2016 Q3 | - USD | 0.0% |
2016 Q2 | - USD | 0.0% |
2016 Q1 | - USD | 0.0% |
2015 Q2 | - USD | 0.0% |
2015 FY | - USD | 0.0% |
2015 Q4 | - USD | 0.0% |
2015 Q3 | - USD | 0.0% |
2015 Q1 | - USD | 0.0% |
2014 Q2 | - USD | 0.0% |
2014 Q1 | - USD | 0.0% |
2014 FY | - USD | 0.0% |
2014 Q4 | - USD | 0.0% |
2014 Q3 | - USD | 0.0% |
2013 Q4 | - USD | 0.0% |
2013 Q3 | - USD | 0.0% |
2013 Q2 | - USD | 0.0% |
2013 FY | - USD | 0.0% |
2013 Q1 | - USD | 0.0% |
2012 Q4 | - USD | 0.0% |
2012 Q2 | - USD | 0.0% |
2012 Q3 | - USD | 0.0% |
2012 FY | - USD | 100.0% |
2012 Q1 | - USD | 100.0% |
2011 Q4 | -35.13 Thousand USD | -443.98% |
2011 Q1 | -3200.00 USD | -123.17% |
2011 Q2 | -6237.00 USD | -94.91% |
2011 Q3 | 10.21 Thousand USD | 263.78% |
2011 FY | -34.36 Thousand USD | -211.14% |
2010 Q1 | 10.42 Thousand USD | 127.79% |
2010 Q2 | 2827.00 USD | -72.88% |
2010 Q3 | 3858.00 USD | 36.47% |
2010 Q4 | 13.81 Thousand USD | 257.96% |
2010 FY | 30.91 Thousand USD | 100.16% |
2009 Q2 | 20.11 Thousand USD | 195.51% |
2009 Q4 | -37.5 Thousand USD | -244.11% |
2009 Q3 | 26.02 Thousand USD | 29.35% |
2009 FY | 15.44 Thousand USD | -67.04% |
2009 Q1 | 6808.00 USD | 16.64% |
2008 Q3 | 23.46 Thousand USD | 87.58% |
2008 Q1 | 5051.00 USD | 111.16% |
2008 FY | 46.86 Thousand USD | 812.05% |
2008 Q2 | 12.51 Thousand USD | 147.69% |
2008 Q4 | 5837.00 USD | -75.13% |
2007 Q4 | -45.25 Thousand USD | -370.4% |
2007 Q1 | 16.15 Thousand USD | -4.92% |
2007 Q2 | 5778.00 USD | -64.24% |
2007 Q3 | 16.73 Thousand USD | 189.63% |
2007 FY | -6582.00 USD | -114.82% |
2006 FY | 44.41 Thousand USD | 146.42% |
2006 Q2 | 16.93 Thousand USD | -22.72% |
2006 Q3 | -11.43 Thousand USD | -167.49% |
2006 Q4 | 16.99 Thousand USD | 248.64% |
2006 Q1 | 21.92 Thousand USD | 144.69% |
2005 Q2 | -27.37 Thousand USD | -294.89% |
2005 Q4 | -49.04 Thousand USD | -297.44% |
2005 Q1 | -6933.00 USD | -1137.87% |
2005 FY | -95.69 Thousand USD | -264.89% |
2005 Q3 | -12.34 Thousand USD | 54.93% |
2004 Q2 | -17.65 Thousand USD | -1185.15% |
2004 FY | -26.22 Thousand USD | -14231.15% |
2004 Q4 | 668.00 USD | 113.34% |
2004 Q1 | -1374.00 USD | 0.0% |
2004 Q3 | -5009.00 USD | 71.63% |
2003 Q2 | - USD | 0.0% |
2003 FY | -183.00 USD | 0.0% |
2003 Q4 | - USD | 0.0% |
2003 Q1 | - USD | 0.0% |
2003 Q3 | - USD | 0.0% |
2002 Q2 | - USD | 0.0% |
2002 Q1 | - USD | 0.0% |
2002 FY | - USD | 0.0% |
2002 Q4 | - USD | 0.0% |
2002 Q3 | - USD | 0.0% |
2001 Q2 | - USD | 0.0% |
2001 Q4 | - USD | 0.0% |
2001 FY | - USD | 0.0% |
2001 Q3 | - USD | 0.0% |
2001 Q1 | - USD | 0.0% |
2000 Q4 | - USD | 0.0% |
2000 Q2 | - USD | 0.0% |
2000 Q1 | - USD | 0.0% |
2000 FY | - USD | 0.0% |
2000 Q3 | - USD | 0.0% |
1999 Q2 | - USD | 0.0% |
1999 Q3 | - USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
America Great Health | 168.58 Thousand USD | 93.113% |
Ampio Pharmaceuticals, Inc. | -250 Thousand USD | 104.644% |
Aridis Pharmaceuticals, Inc. | - USD | -Infinity% |
Biora Therapeutics, Inc. | -551 Thousand USD | 102.107% |
Bio-Path Holdings, Inc. | -178 Thousand USD | 106.522% |
Better Therapeutics, Inc. | -2.72 Million USD | 100.425% |
Calithera Biosciences, Inc. | -1.38 Million USD | 100.838% |
Comera Life Sciences Holdings, Inc. | 422.71 Thousand USD | 97.253% |
Gene Biotherapeutics, Inc. | - USD | -Infinity% |
eFFECTOR Therapeutics, Inc. | -22.91 Million USD | 100.051% |
Eloxx Pharmaceuticals, Inc. | - USD | -Infinity% |
Evelo Biosciences, Inc. | - USD | -Infinity% |
Evolutionary Genomics, Inc. | -1.02 Million USD | 101.137% |
Finch Therapeutics Group, Inc. | -7.09 Million USD | 100.164% |
Galera Therapeutics, Inc. | -259 Thousand USD | 104.483% |
Innovation1 Biotech Inc. | -52.69 Thousand USD | 122.031% |
Kiromic BioPharma, Inc. | -2.79 Million USD | 100.415% |
Molecular Templates, Inc. | 50.39 Million USD | 99.977% |
Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | 109.732% |
NexImmune, Inc. | -1.02 Million USD | 101.133% |
Orgenesis Inc. | -5.72 Million USD | 100.203% |
Panbela Therapeutics, Inc. | -25.64 Million USD | 100.045% |
Point of Care Nano-Technology, Inc. | -4601.00 USD | 352.336% |
PaxMedica, Inc. Common Stock | - USD | -Infinity% |
Scopus BioPharma Inc. | - USD | -Infinity% |
Sorrento Therapeutics, Inc. | 29.38 Million USD | 99.96% |
Statera Biopharma, Inc. | -488.31 Thousand USD | 102.378% |
TRACON Pharmaceuticals, Inc. | -232 Thousand USD | 105.004% |
Trevena, Inc. | 1.45 Million USD | 99.202% |
Vaxxinity, Inc. | -2.23 Million USD | 100.52% |
Vaccinex, Inc. | -16 Million USD | 100.073% |
Vicapsys Life Sciences, Inc. | - USD | -Infinity% |
Viracta Therapeutics, Inc. | -492 Thousand USD | 102.36% |